Please use this identifier to cite or link to this item:
|Title:||Inhibition of 3-D tumor spheroids by timed-released hydrophilic and hydrophobic drugs from multilayered polymeric microparticles||Authors:||Tan, Ern Yu
Loo, Say Chye Joachim
Lee, Wei Li
Guo, Wei Mei
Ho, Vincent H. B.
Chong, Han Chung
Tan, Nguan Soon
|Keywords:||DRNTU::Science::Biological sciences||Issue Date:||2014||Source:||Lee, W. L., Guo, W. M., Ho, V. H. B., Saha, A., Chong, H. C., Tan, N. S., et al. (2014). Inhibition of 3-D tumor spheroids by timed-released hydrophilic and hydrophobic drugs from multilayered polymeric microparticles. Small, 10(19), 3986-3996.||Series/Report no.:||Small||Abstract:||First-line cancer chemotherapy necessitates high parenteral dosage and repeated dosing of a combination of drugs over a prolonged period. Current commercially available chemotherapeutic agents, such as Doxil and Taxol, are only capable of delivering single drug in a bolus dose. The aim of this study is to develop dual-drug-loaded, multilayered microparticles and to investigate their antitumor efficacy compared with single-drug-loaded particles. Results show hydrophilic doxorubicin HCl (DOX) and hydrophobic paclitaxel (PTX) localized in the poly(dl-lactic-co-glycolic acid, 50:50) (PLGA) shell and in the poly(l-lactic acid) (PLLA) core, respectively. The introduction of poly[(1,6-bis-carboxyphenoxy) hexane] (PCPH) into PLGA/PLLA microparticles causes PTX to be localized in the PLLA and PCPH mid-layers, whereas DOX is found in both the PLGA shell and core. PLGA/PLLA/PCPH microparticles with denser shells allow better control of DOX release. A delayed release of PTX is observed with the addition of PCPH. Three-dimensional MCF-7 spheroid studies demonstrate that controlled co-delivery of DOX and PTX from multilayered microparticles produces a greater reduction in spheroid growth rate compared with single-drug-loaded particles. This study provides mechanistic insights into how distinctive structure of multilayered microparticles can be designed to modulate the release profiles of anticancer drugs, and how co-delivery can potentially provide better antitumor response.||URI:||https://hdl.handle.net/10356/103481
|ISSN:||1613-6810||DOI:||http://dx.doi.org/10.1002/smll.201400536||Rights:||© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||MSE Journal Articles|
SBS Journal Articles
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.